134 filings
6-K
CALT
Calliditas Therapeutics AB
6 Mar 24
Current report (foreign)
4:05pm
6-K
CALT
Calliditas Therapeutics AB
21 Feb 24
Calliditas Year-end report, January – December 2023
4:05pm
6-K
CALT
Calliditas Therapeutics AB
8 Jan 24
Calliditas Therapeutics appoints Maria Törnsén as President North America
8:28am
6-K
CALT
Calliditas Therapeutics AB
27 Dec 23
Current report (foreign)
4:05pm
6-K
CALT
Calliditas Therapeutics AB
20 Dec 23
Current report (foreign)
5:13pm
6-K
CALT
Calliditas Therapeutics AB
11 Dec 23
Current report (foreign)
4:05pm
6-K
CALT
Calliditas Therapeutics AB
30 Nov 23
Current report (foreign)
4:05pm
6-K
CALT
Calliditas Therapeutics AB
24 Nov 23
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy
4:05pm
6-K
CALT
Calliditas Therapeutics AB
7 Nov 23
Interim Report January – September 2023 Q3
4:05pm
6-K
CALT
Calliditas Therapeutics AB
23 Oct 23
Calliditas Therapeutics’ nomination committee composition for the AGM 2024
4:05pm
6-K
CALT
Calliditas Therapeutics AB
5 Oct 23
Current report (foreign)
4:05pm
6-K
CALT
Calliditas Therapeutics AB
27 Sep 23
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
4:04pm
6-K
CALT
Calliditas Therapeutics AB
18 Aug 23
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
4:05pm
6-K
CALT
Calliditas Therapeutics AB
17 Aug 23
Filing for full approval of TARPEYO
4:05pm
6-K
CALT
Calliditas Therapeutics AB
17 Jul 23
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
4:05pm
6-K
CALT
Calliditas Therapeutics AB
21 Jun 23
Current report (foreign)
4:05pm
S-8
CALT
Calliditas Therapeutics AB
12 Jun 23
Registration of securities for employees
4:06pm
6-K
CALT
Calliditas Therapeutics AB
8 Jun 23
Current report (foreign)
4:05pm
6-K
CALT
Calliditas Therapeutics AB
30 May 23
Adoption of income statement and balance sheet for the financial year 2022 and discharge from liability
4:21pm
6-K
CALT
Calliditas Therapeutics AB
16 May 23
Current report (foreign)
4:05pm